SLEEP 2020: The gospel of insomniacs, Daridorexant's Phase III clinical progress.

Pharmaceutical company Idorsia announced today that a Phase III clinical study has shown positive results in adult and elderly insomnia patients with double Orexin subject antagonist daridorexant.
results will be presented at the Sleep Conference 2020 (SLEEP 2020).
Dr Thomas Roth, director of the Sleep Disorders and Research Centre at Henry Ford Hospital, commented: "Daridorexant is a new dual Orexin subjecttagonist whose pharmacodynamic and pharmacodynamic characteristics are optimized for sleep seizures and duration of action to improve nighttime efficacy without residual effects."
Phase III clinical trials are designed to assess the effectiveness and safety of the dridorexant treatment for patients with moderate to severe insomnia.
used a multi-guide sleep monitor to assess wake-up (WASO) and persistent sleep incubation period (LPS) after a sleep attack.
sleep journal questionnaire is used to measure subjective total sleep time (sTST).
to assess daytime function using the newly developed and validated patient reporting outcome tool, the Insomnia DayTime Symptoms and Impact Questionnaire (IDSIQ).
results showed that Daridorexant significantly improved sleep maintenance compared to placebo.
the average changes in WASO (minutes) relative to baselines in patients with placebo, 25 mg daridorexant and 50 mg daridorexant were -6.2, -18.4 and -29.0 (at 1 month) and -11.1, -23.0 and -29.4 at 3 months, respectively.
.